Mission Therapeutics is a drug discovery and development company engaged in selectively targeting deubiquitylating enzymes (DUBs) with small molecule inhibitors to effectively treat patients with serious and life-threatening diseases.
We have built a world-leading proprietary platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant clinical and commercial interest.
Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programs may be advanced in partnership with other pharmaceutical companies.
Through application of our DUB platform, we have the potential to explore multiple additional DUB targets relevant to other diseases, and we invite enquiries for strategic partnerships from other pharmaceutical companies or academics.
We are collaborating with AbbVie in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Read more
Mission and Pfizer Inc. have also expanded their relationship by entering into an evaluation and option agreement for DUB target validation. Read more
We have a collaborative, science-driven culture that is enhanced through a range of strategic relationships with leading academic, research and medical centers, research charities and through partnerships with other companies.
We have an extensive network of collaborators, including: